A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With An Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects With Episodic Migraine
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Atogepant (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Registrational; Therapeutic Use
- Acronyms JPN PIVOTAL; Release
- Sponsors AbbVie
Most Recent Events
- 17 Mar 2025 Status changed from active, no longer recruiting to completed.
- 19 Dec 2024 Planned primary completion date changed from 2 Nov 2024 to 1 Mar 2025.
- 22 Aug 2024 Planned End Date changed from 28 May 2025 to 1 Mar 2025.